

RECEIVED


Form PTO-1449

Docket Number 391442003700

Application Number 09/533,714

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)



Applicant

Gary Bridger

NOV 30 2000

Filing Date March 24, 2000

Group Art Unit: 1633

TECH CENTER 1600/2000

Mailing Date November 22, 2000

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
VB	1.	12/1996	5,583,131	Bridger et al.	514	183	
VB	2.	12/1997	5,698,546	Bridger et al.	514	183	
VB	3.	10/1998	5,817,807	Bridger et al.	540	474	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
VB	4.	02/1999	WO 99/04794A	PCT			
VB	5.	06/1991	EP 0 434 385 A	EPO			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
VB	6.	Carroll R., et al. (1997). <i>Science</i> 276:273-276.
VB	7.	Casella L., et al. (1996). <i>Inorganic Chem</i> 35:7516-7525.
VB	8.	Donzella G., et al. (1998). <i>Nature Medicine</i> 4:72-77.
VB	9.	Ghosh D., et al. (1998). <i>Inorganic Chem</i> 37:6597-6605.
VB	10.	Gultneh Y., et al. (1995). <i>Inorganic Chem</i> 34:3633-3645.
VB	11.	Gupta S., et al. (1998). <i>J. Biol Chem</i> 7:4282-4287.
VB	12.	Kanda W., et al. (1995). <i>Angew Chem Int Ed Engl</i> 34:588-590.
VB	13.	Miedema F., et al. (1994). <i>Immune Rev</i> 140:35-72.
VB	14.	Peled A., et al. (1998). <i>Science</i> 283:845-848.
VB	15.	Ponath P. (1998). <i>Exp Opin Invest Drugs</i> 7:1-18.
VB	16.	Schols D., et al. (1997). <i>J Exp Med</i> 186:1383-1388.
VB	17.	Schols D., et al. (1997). <i>Antiviral Research</i> 35:147-156.
VB	18.	Tachibana K., et al. (1998). <i>Nature</i> 393:591-594.
VB	19.	Wyatt R., et al. (1998). <i>Science</i> 280:1884-1888.

EXAMINER: V. Balasubramaniam


DATE CONSIDERED:

12/27/01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

Form PTO-1449				Docket Number 391442003900	Application Number 09/535,314
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Gary BRIDGER	SEP 01 2001 TECH CENTER 1600/2900
				Filing Date March 24, 2000	Group Art Unit 1633
				Hand Delivery Date: August 28, 2000	



## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
-------------------	----------	------	--------------	------	-------	----------	----------------------------

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
VB	1.	07/01/1999	WO 99/32100	PCT			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
VM	2.	Biard-Piechaczyk et al., 1999 "Role of CXCR4 in HIV-1-induced Apoptosis of Cells with a CD4+, CXCR4+ Phenotype" Immunology Letters 70 (1999) 1-3
VM	3.	Blanco, et al., 2000 "The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelop-Induced Apoptosis" American Society for Microbiology, January 2000, p. 51-56
VM	4.	Fedyk, et al. "Maturation Decreases Responsiveness of Human Bone Marrow B Lineage Cells to Stromal-Derived Factor 1 (SDF-1)", Journal of Leukocytic Biology, 66, P.667
VM	5.	Herbein et al., 1998 "Apoptosis of CD8+ T cells is Mediated by Macrophages Through Interaction of HIV gp 120 with Chemokine Receptor CXCR4" Nature 395, 1998, pp. 189-193.
VM	6.	Hesselgesser et al., 1997 "CD4-Independent Association Between HIV-1 gp 120 and CXCR4: Functional Chemokine Receptors are Expressed in Human Neurons", Current Biology, 7(2), pp. 112-121.
VM	7.	Hesselgesser et al. 1998 "Neuronal Apoptosis Induced by HIV-1 gp 120 and the Chemokine SDF-1 $\alpha$ is Mediated by the Chemokine Receptor CXCR4" Current Biology, 8 (10), pp. 595-598
VM	8.	Lee et al., 1999 "Coreceptor/Chemokine Receptor Expression on Human Hematopoietic Cells: Biological Implications for Human Immunodeficiency Virus-Type 1 Infection" Blood, 93(4), pp. 1145-1156
VM	9.	Nikolic et al., 1998 "The p35/Cdk5 Kinase Is a Neuron-Specific Rac Effector That Inhibits Pak1 Activity", Nature 395, 194
VM	10.	Ohagen et al., 1999 "Apoptosis Induced by Infection of Primary Brain Cultures with Diverse Human Immunodeficiency Virus Type 1 Isolates: Evidence for a Role of the Envelop" Journal of Virology, 73(2), pp. 897-906

EXAMINER: (examiner)

V. Balasubramanya

DATE CONSIDERED:

12/27/01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 391442003700	Application Number 09/535,314
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Gary BRIDGER et al.	<b>RECEIVED</b>
		Filing Date March 24, 2000	Group Art Unit 1633 <i>SEP 01 2000</i>
		Hand Delivery Date: August 28, 2000 <i>TECH CENTER 1600/2900</i>	

VM	11.	Schramm et al., 2000 "Viral Entry through CXCR4 Is a Pathogenic Factor and Therapeutic Target in Human Immunodeficiency Virus Type 1 Disease", Journal of Virology, Jan, 2000, p. 184-192
----	-----	---



EXAMINER: <u>V. Balasubramanian</u>	DATE CONSIDERED: <u>12/27/01</u>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
PTO/SB/08 (2-92) dc-223860	
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	